Assessment of non-derivatized beta-N-methylamino-L-alanine (BMAA) neurotoxin in free form in urine of patients with nonspecific neurological symptoms

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F17%3A00100223" target="_blank" >RIV/00216224:14310/17:00100223 - isvavai.cz</a>

Result on the web

<a href="https://www.sciencedirect.com/science/article/pii/S0041010117301277?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0041010117301277?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.toxicon.2017.04.011" target="_blank" >10.1016/j.toxicon.2017.04.011</a>

Result language

angličtina

Original language name

Assessment of non-derivatized beta-N-methylamino-L-alanine (BMAA) neurotoxin in free form in urine of patients with nonspecific neurological symptoms

Original language description

The beta-N-methylamino-L-alanine (BMAA) is a non-proteinogenic amino acid discussed to be produced by cyanobacteria forming harmful blooms. Since BMAA is suspected etiological agent in neurodegenerative diseases, there is a need to study and validate whether and in what concentrations can BMAA be present in human tissues. The aim of the present study was to validate analytical and extraction procedures for quantification of non-derivatized BMAA in the urine using liquid chromatography and commercial ELISA Kit. The study was focused on BMAA in different forms - dissolved, protein associated and total. The validated protocol included SPE followed by HILIC MS/MS for analyses of non-derivatized free form of BMAA with a limit of quantification 20 ng/mL. The methods for other BMAA forms (i.e.protein-associated and total) were also assessed but high matrix interferences did not allow their implementation. The method was used for analyses of free BMAA in 23 urine samples from healthy volunteers and psychiatric patients suffering from nonspecific neurological symptoms. Traces of BMAA were suspectedly detected in a single urine sample but they were not unequivocally proved according to all conservative analytical criteria. BMAA was also not confirmed in a repeatedly collected sample from the same person. The evaluated commercial BMAA ELISA Kit (Abraxis) was not suitable for determination of BMAA in extracted urine samples because of systematically highly false positive results. In agreement with recent findings, analyses of BMAA appear to methodologically challenging, and further research on BMAA in human tissues (or its precursors with potency to form BMAA under natural conditions or eventually - during sample processing) is needed to clarify its potential ethiological role in neurodegenerative diseases.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Toxicon

ISSN

0041-0101

e-ISSN

—

Volume of the periodical

133

Issue of the periodical within the volume

July

Country of publishing house

GB - UNITED KINGDOM

Number of pages

10

Pages from-to

48-57

UT code for WoS article

000403864000006

EID of the result in the Scopus database

2-s2.0-85018781200